fda and tirzepatide Grants a New Indication for Obesity Management F.D.A. Approves New Obesity Drug
Description
GLP-1 weight loss medications have transformed obesity treatment, but their price tag raises questions

Roche reported positive Phase II topline data showing that its once-weekly dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist CT-388 achieved substantial, sustained, and dose-dependent weight loss through 48 weeks

MAPS Split is an advanced muscle building and body sculpting program designed for the experienced lifter, bodybuilder, physique competitor and bikini competitor
Discover the weight loss benefits of topiramate and learn how to use it effectively

Future of Diabetes Management
Medicare Part D currently does NOT cover GLP-1 receptor agonists for weight loss or obesity aloneonly for type 2 diabetes
